Floatz logo

Vericiguat

Cardiac Dysfunction

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

26 Active assets in the Cardiac Dysfunction cohort.

Asset / SponsorPhaseRating
Empagliflozin
Jacob Moller
Phase 4BB
Finerenone
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Phase 4BB
CARVEDILOL
Abramson Cancer Center at Penn Medicine
Phase 3BB
Semaglutide
University Medical Centre Ljubljana
Phase 2/3BB
Rivaroxaban
Janssen Research & Development, LLC
Phase 3B

View all 40 →

Same molecule, other indications

Vericiguat is also rated in:

coronary microvascular disorderDormant
B
Indicative ·
57 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
CCC
Indicative ·
54 / 100
View asset →
cardiovascular disorderDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →